These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26712818)

  • 1. Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.
    Hartmann G; Kumar S; Johns D; Gheyas F; Gutstein D; Shen X; Burton A; Lederman H; Lutz R; Jackson T; Chavez-Eng C; Mitra K
    Drug Metab Dispos; 2016 Mar; 44(3):428-34. PubMed ID: 26712818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
    Krishna R; Gheyas F; Liu Y; Hagen DR; Walker B; Chawla A; Cote J; Blaustein RO; Gutstein DE
    Clin Pharmacol Ther; 2017 Nov; 102(5):832-840. PubMed ID: 28380664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
    Johns DG; Wang SP; Rosa R; Hubert J; Xu S; Chen Y; Bateman T; Blaustein RO
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00543. PubMed ID: 31832204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes.
    Johns DG; LeVoci L; Krsmanovic M; Lu M; Hartmann G; Xu S; Wang SP; Chen Y; Bateman T; Blaustein RO
    Drug Metab Dispos; 2019 Mar; 47(3):227-233. PubMed ID: 30567880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Panebianco D; Cote J; Bergman AJ; Van Hoydonck P; Laethem T; Van Dyck K; Chen J; Chavez-Eng C; Archer L; Lutz R; Hilliard D; Snyder K; Jin B; Van Bortel L; Lasseter KC; Al-Huniti N; Dykstra K; Gottesdiener K; Wagner JA
    Br J Clin Pharmacol; 2009 Oct; 68(4):535-45. PubMed ID: 19843057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
    Äijänen T; Koivuniemi A; Javanainen M; Rissanen S; Rog T; Vattulainen I
    PLoS Comput Biol; 2014 Nov; 10(11):e1003987. PubMed ID: 25412509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.
    Zhu L; Luu T; Emfinger CH; Parks BA; Shi J; Trefts E; Zeng F; Kuklenyik Z; Harris RC; Wasserman DH; Fazio S; Stafford JM
    Diabetes; 2018 Dec; 67(12):2494-2506. PubMed ID: 30213825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
    Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
    Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):628-36. PubMed ID: 25633313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
    Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    Am J Cardiol; 2014 Jan; 113(1):76-83. PubMed ID: 24188894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
    Krishna R; Gheyas F; Liu Y; Cote J; Laterza O; Ruckle JL; Wagner JA; Denker AE
    J Clin Pharmacol; 2018 Feb; 58(2):254-262. PubMed ID: 28884824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
    Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ
    J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.
    Small DS; Ke AB; Hall SD; Mantlo N; Rotelli M; Friedrich S
    J Clin Pharmacol; 2015 Jul; 55(7):757-67. PubMed ID: 25651523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.